[1] 陆再英,钟南山,谢毅,等.内科学[M].北京:人民卫生出版社,1984:770.
[2] Aguiar,Toledo E.Doença vascuilar periférica[J].Rev Soc Cardiol Estado de Säo Paulo,1998, 8(5):971-980.
[3] Domingueti CP,Dusse LM,Carvalho Md,et al.Hypercoagulability and cardiovascular disease in diabetic nephropathy[J].Clin Chim Acta,2013,415:279-285.
[4] Giannini C,Mohn A,Chiarelli F,et al.Macrovascular angiopathy in children and adolescents with type 1 diabetes[J].Diabetes Metab Res Rev,2011,27(5):436-460.
[5] Lelario,Carlos A.Diabete melito:aspectos epidemiológico[J].Rev Soc Cardiol Estado de Säo Paulo,1998,8(5):885-891.
[6] Romäo JE Jr.Doença renal crônica:Definição,epidemiologia e classificação[J].J Bras Nefrol, 2004,26(3):1-3.
[7] Karnib HH,Ziyadeh FN.The cardiorenal syndrome in diabetes mellitus[J].Diabetes Res Clin Pract,2010,89(3):201-208.
[8] Goldberg RB.Cytokine and cytokine-like inflammation markers, endothelial dysfunction,and imbalance coagulation in development of diabetes and its complications[J]. J Clin Endocrinol Metab,2009, 94(9):3171-3182.
[9] Wautier JL,Guillausseau PJ.Diabetes, advanced glycation endproducts and vascular disease[J]. Vasc Med,1998,3(2):131-137.
[10] Kessler L,Wiesel ML,Attali P,et al.Von Willebrand factor in diabetic angiopathy[J].Diabetes Metab,1998,24(4):327-336.
[11] Margetic S.Inflammation and haemostasis[J].Biochem Med,2012,22(1):49-62.
[12] Yamagishi S,Matsui T.Advanced glycation end products,oxidative stress and diabetic nephropathy[J].Oxid Med Cell Longev,2010, 3(2):101-108.
[13] Libby P,Ridker PM,Hansson GK.Inflammation in atherosclerosis: from pathophysiology to practice[J].J Am Coll Cardiol,2009,54(23):2129-2138.
[14] Dubin R,Cushman M,Folsom AR,et al.Kidney function and multiple hemostatic markers:cross sectional associations in the multi-ethnic study of atherosclerosis[J].BMC Nephrol,2011,12:3.
[15] 龙兆丰,屈国云,徐敏.血浆D-二聚体与2型糖尿病微血管病变的关系[J].湖南医科大学学报,2001,26(5):434-436.
[16] El Asrar MA, Adly AA, El Hadidy ES, et al.D-dimer levels in type 1 and type 2 diabetic children and adolescents; Relation to microvascular complications and dyslipidemia “own data and review”[J].Pediatr Endocrinol Rev,2012,9(3):657-668.
[17] Domingueti CP,Dusse LM,Fóscolo RB,et al.Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes Mellitus[J].PLoS One, 2015,10(7):e0132784.
[18] Wakabayashi I,Masuda H.Association of D-dimer with microalbuminuria in patients with type 2 diabetes mellitus[J].J Thromb Thrombolysis,2009,27(1):29-35.
[19] Soares AL,Rosário PW,Borges MA,et al.PAI-1 and D-dimer in type 2 diabetic women with asymptomatic macrovascular disease assessed by carotid Doppler[J]. Clin Appl Thromb Hemost, 2010,16(2):204-208.
[20] Nwose EU,Richards RS,Jelinek HF,et al.D-dimer identifies stages in the progression of diabetes mellitus from family history of diabetes to cardiovascular complications[J]. Pathology,2007, 39(2):252-257.
[21] Krupinski J,Turu MM,Font MA,et al.Increased tissue factor, MMP-8,and D-dimer expression in diabetic patients with unstable advanced carotid atherosclerosis[J].Vasc Health Risk Manag, 2007,3(4):405-412.
[22] Targher G,Bertolini L,Zoppini G,et al.Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy[J].Diabet Med,2005,22(8): 999-1004.
[23] Astrup AS,Tarnow L,Pietraszek L,et al.Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: associations with mortality and decline of glomerular filtration rate[J].Diabetes Care, 2008,31(6):1170-1176.
[24] Erem C,Hacihasanoğlu A,Celik S,et al.Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications[J].Med Princ Pract, 2005,14(1):22-30.
[25] Hagiwara H,Kaizu K,Uriu K,et al.Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models[J].Thromb Res,2003,111(4-5):301-309.
[26] Verkleij CJ,Bruijn RE,Meesters EW,et al.The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease[J].Clin Appl Thromb Hemost,2011,17(6): E57-63.
[27] Zareba W,Pancio G,Moss AJ,et al.Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients.THROMBO Investigators[J].Thromb Haemost,2001,86(3):791-799.
[28] Pratte KA,Barón AE,Ogden LG,et al.Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes[J].J Diabetes Complications,2009,23(6):387-393. |
